BioCryst Pharmaceuticals Reports $156.4M Revenue in Q1 2026, Faces $721.8M Net Loss

BioCryst Pharmaceuticals, Inc. reported a total revenue of $156.4 million for the first quarter of 2026, marking an increase from $145.5 million in the same period of the previous year. This growth was primarily driven by a $25.6 million rise in sales of its flagship product, ORLADEYO, which reached $148.3 million, attributed to strong patient demand and a net price increase. However, the company experienced a decrease in revenue from its European ORLADEYO business, which was sold to Neopharmed in October 2025, resulting in a $11.5 million drop in associated revenues. Additionally, license revenue rose to $3.0 million, reflecting quarterly royalty payments from BioCryst Ireland Limited.

The company's financial performance was significantly impacted by a one-time expense of $697.8 million related to acquired in-process research and development (IPR&D) from its recent merger with Astria Therapeutics, which closed on January 23, 2026. This merger also contributed to a substantial increase in research and development expenses, which rose to $60.3 million from $37.3 million year-over-year, largely due to increased personnel costs and expenses associated with the integration of Astria's operations. Selling, general, and administrative expenses also increased to $94.6 million, up from $82.5 million, driven by costs related to the merger and separation agreements with Astria employees.

As of March 31, 2026, BioCryst's total assets were reported at $465.1 million, a decrease from $514.2 million at the end of 2025. The company's liabilities surged to $1.02 billion, primarily due to the new Blackstone Loan Agreement, which provided $400 million in term loans to finance the Astria acquisition. The company's stockholders' deficit widened to $553.8 million, compared to $119.2 million at the end of the previous fiscal year, reflecting the impact of the merger-related expenses.

In terms of operational metrics, BioCryst's cash and cash equivalents increased to $171.6 million, up from $89.7 million at the end of 2025, bolstered by financing activities that included proceeds from the Blackstone Loan Agreement. The company reported a net loss of $721.8 million for the quarter, compared to a net income of $32,000 in the prior year, primarily due to the aforementioned IPR&D expense. Looking ahead, BioCryst anticipates that its financial resources will be sufficient to fund operations for at least the next 12 months, contingent on the successful commercialization of ORLADEYO and the progression of its product candidates.